Program
Moxifloxacin
Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.
Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.
Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 200 open or running | phase 4since Jun 26, 2007 | Nov 21, 2006 | none ahead |
| Alconits history only | 140 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Jul 10, 2007 | Jul 10, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 1since Oct 8, 2009 | Oct 8, 2009 | none ahead |
| Da Volterraits history only | 20 open or running | phase 1since Jun 25, 2014 | Jun 25, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 21 open or running | phase 3since Jul 30, 2025 | Apr 9, 2024 | none ahead |
| Richmond Pharmacologyits history only | 20 open or running | phase 1since Jun 19, 2012 | Jun 19, 2012 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Adapt Produtos Oftalmológicos Ltda.its history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Jan 1, 2016 | Jan 1, 2016 | none ahead |
| Jason Ahee, M.D.its history only | 11 open or running | phase 3since Aug 4, 2017 | Aug 4, 2017 | Oct 2030phase 3 · NCT03244072 |
| Research Insightits history only | 10 open or running | phase 4since Dec 18, 2019 | Dec 18, 2019 | none ahead |
| Richmond Research Instituteits history only | 10 open or running | phase 1since Nov 8, 2013 | Nov 8, 2013 | none ahead |
Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Sep 7, 2005.
- May 22, 2013Phase 1 study in HealthyPfizer · NCT01862887 · 48 enrolled · United States
- Nov 8, 2013Richmond Research Institute’s first study: phase 1 study in Diabetes MellitusNew to Richmond Research InstituteRichmond Research Institute · NCT01984827 · 24 enrolled · United Kingdom
- Jun 25, 2014Da Volterra’s first study: phase 1 study in HealthyNew to Da VolterraDa Volterra · NCT02176005 · 44 enrolled · France
- Dec 18, 2014Dr. Reddy's Laboratories’ first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02322619 · 26 enrolled
- Jan 1, 2016Intarcia Therapeutics’ first study: phase 1 study in Healthy Adult Male and Female VolunteersNew to Intarcia TherapeuticsIntarcia Therapeutics · NCT02650479 · 82 enrolled · Netherlands
- Sep 19, 2016Phase 1 study in Healthy SubjectsDa Volterra · NCT02917200 · 150 enrolled · France
- May 18, 2017Phase 1 study in Healthy VolunteersPfizer · NCT03162900 · 36 enrolled · Belgium
- Aug 4, 2017Jason Ahee, M.D.’s first study: phase 3 study in EndophthalmitisNew to Jason Ahee, M.D.Jason Ahee, M.D. · NCT03244072 · 60,000 planned · United States
- Dec 18, 2019Research Insight’s first study: phase 4 study in CataractNew to Research InsightResearch Insight · NCT04273282 · 31 enrolled · United States
- Jan 29, 2020Phase 1 study in Healthy SubjectsViatris · NCT04255277 · 97 enrolled · France
- Jul 28, 2022Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT05481528 · 51 enrolled · Germany
- Apr 18, 2023No phase study in Diabetes Mellitus, Type 2Richmond Pharmacology · NCT07014735 · 14 enrolled · United Kingdom
- Apr 9, 2024Laboratorios Sophia S.A de C.V.’s first study: phase 1 study in Conjunctivitis, BacterialNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT06363292 · 37 enrolled · Mexico
- Jul 30, 2025Phase 3 study in Cataract ExtractionLaboratorios Sophia S.A de C.V. · NCT07305987 · 134 planned · Mexico
Ahead
- Oct 2030Primary completion: phase 3 study in EndophthalmitisJason Ahee, M.D. · NCT03244072
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07305987Cataract Extraction · Mexico | 3 | Recruiting | Laboratorios Sophia S.A de C.V. | Jun 30, 2026 | 134 |
| NCT06363292Conjunctivitis, Bacterial · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | May 28, 2024 | 37 |
| NCT07014735Diabetes Mellitus, Type 2 · United Kingdom | – | Terminated | Richmond Pharmacology | May 31, 2026 | 14 |
| NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Feb 7, 2023 | 51 |
| NCT04255277Healthy Subjects · France | 1 | Completed | Viatris | Sep 14, 2021 | 97 |
| NCT04273282Cataract · United States | 4 | Completed | Research Insight | Nov 24, 2020 | 31 |
| NCT03244072Endophthalmitis · United States | 3 | Not yet recruiting | Jason Ahee, M.D. | Oct 2030 | 60,000 |
| NCT03162900Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Sep 23, 2017 | 36 |
| NCT02917200Healthy Subjects · France | 1 | Completed | Da Volterra | Dec 2, 2016 | 150 |
| NCT02650479Healthy Adult Male and Female Volunteers · Netherlands | 1 | Completed | Intarcia Therapeutics | Apr 2016 | 82 |
| NCT02322619Healthy | 1 | Completed | Dr. Reddy's Laboratories | Dec 2012 | 26 |
| NCT02176005Healthy · France | 1 | Completed | Da Volterra | Oct 2014 | 44 |
| NCT01984827Diabetes Mellitus · United Kingdom | 1 | Completed | Richmond Research Institute | Dec 31, 2020 | 24 |
| NCT01862887Healthy · United States | 1 | Completed | Pfizer | Aug 2013 | 48 |
| NCT01859702Cataract | 4 | Completed | Alcon | Aug 2012 | 36 |
| NCT01775761TTR Cardiomyopathy · United States, Belgium, Singapore | 1 | Completed | Pfizer | Apr 2013 | 42 |
| NCT01642485Insulin Resistance · United Kingdom | 1 | Completed | Richmond Pharmacology | Sep 2011 | 32 |
| NCT01573910Conjunctivitis, Bacterial · China | 3 | Completed | Alcon | Apr 2014 | 985 |
| NCT01515826Cataract | 3 | Withdrawn | Alcon | Oct 2014 | 0 |
| NCT01449188Nausea · United States | 1 | Completed | GlaxoSmithKline | Dec 19, 2011 | 60 |
| NCT01406262Diabetes Mellitus, Type 2 | 1 | Completed | GlaxoSmithKline | Dec 29, 2011 | 94 |
| NCT01603030Eye Infections · Brazil | 3 | UNKNOWN | Adapt Produtos Oftalmológicos Ltda. | Aug 2012 | 66 |
| NCT01238783Conjunctivitis, Bacterial | 2 | Withdrawn | Alcon | Dec 2011 | 0 |
| NCT01073891Healthy · Germany | 1 | Completed | Bayer | Nov 2010 | 24 |
| NCT01071902Otitis Media · United States | 3 | Terminated | Alcon | Oct 2011 | 400 |
| NCT01069900Intraabdominal Infections · United States, Argentina, Bulgaria and more | 3 | Completed | Bayer | Jan 21, 2015 | 458 |
| NCT01049022Infections · United States | 1 | Completed | Bayer | Dec 2012 | 31 |
| NCT01045902Pneumonia, Aspiration · Germany | 3 | Completed | Bayer | 139 | |
| NCT01014247QTc Evaluation · Australia, Germany, Singapore and more | 1 | Completed | Bayer | Jun 2010 | 56 |
| NCT00996021Healthy Subjects · United States | 1 | Completed | GlaxoSmithKline | Nov 2009 | 42 |
| NCT00840580Cataract · Korea, Republic of | 4 | Completed | Alcon | Sep 2009 | 79 |
| NCT00828971Communicable Diseases · Italy | 3 | Completed | Bayer | Sep 2009 | 16 |
| NCT00798577Conjunctivitis, Bacterial · United States | 4 | Completed | Alcon | Feb 2009 | 24 |
| NCT00769171Intraabdominal Infections · China, Hong Kong, Indonesia and more | 3 | Completed | Bayer | Dec 2006 | 364 |
| NCT00870103Cataract · United States | 4 | Completed | Alcon | Feb 2009 | 64 |
| NCT00750633Otitis Externa | 3 | Completed | Alcon | Jan 2009 | 990 |
| NCT00717561Pneumonia · Italy | 3 | Completed | Bayer | May 2009 | 60 |
| NCT00683865Pelvic Inflammatory Disease · Denmark, Finland, France and more | 3 | Completed | Bayer | Oct 2004 | 749 |
| NCT00668304Maxillary Sinusitis · United States, Argentina | 4 | Completed | Bayer | 192 | |
| NCT00665327Pneumonia · United States, Puerto Rico | 4 | Completed | Bayer | Apr 2004 | 401 |
| NCT00656747Bronchitis, Chronic · Andorra, Argentina, Australia and more | 4 | Completed | Bayer | Dec 2010 | 1,372 |
| NCT00579189Otitis Media | 3 | Completed | Alcon | Jan 2009 | 776 |
| NCT00579020Corneal Diseases · United States | 2 | Terminated | Alcon | Feb 2009 | 144 |
| NCT00578773Otitis Media | 2 | Completed | Alcon | Jan 2009 | 303 |
| NCT00578474Otitis Media | 3 | Completed | Alcon | Aug 2008 | 911 |
| NCT00499642Alzheimer Disease · France | 1 | Completed | Pfizer | ||
| NCT00493038Sinusitis · Italy | 4 | Terminated | Bayer | Jan 2008 | 293 |
| NCT00492726Infections · Argentina, Belgium, Bulgaria and more | 3 | Completed | Bayer | Feb 2009 | 804 |
| NCT00492024Sinusitis · United States | 3 | Completed | Bayer | Mar 2008 | 374 |
| NCT00473460Lung Diseases · United States, Andorra, Argentina and more | 3 | Completed | Bayer | Jan 2007 | 1,404 |
| NCT00453349Pelvic Inflammatory Disease · China, Indonesia, Korea, Republic of and more | 3 | Completed | Bayer | May 2008 | 460 |
| NCT00431678Pneumonia · Argentina, Belgium, Chile and more | 3 | Completed | Bayer | Jul 2005 | 738 |
| NCT00402727Abscess · Austria, Belgium, Bulgaria and more | 3 | Completed | Bayer | Jun 2008 | 813 |
| NCT00312338Conjunctivitis, Bacterial · United States | 4 | Completed | Alcon | Jun 2007 | 137 |
| NCT00158093Hypertension · United States | 1 | Completed | Viatris | 260 |
How it is read
Names in the registry
- “Moxifloxacin”, 32 entries
- “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
- “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
- “moxifloxacin”, 6 entries
- “Moxidex otic solution”, 5 entries
Conditions, from the studies’ own filings
- Cataract, 6 studies
- Conjunctivitis, Bacterial, 5 studies
- Otitis Media, 4 studies
- Sinusitis, 3 studies
- Community-Acquired Pneumonia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.